Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$41.20

0.26 (0.64%)

06:29
07/25/18
07/25
06:29
07/25/18
06:29

GlaxoSmithKline: Restructuring program to deliver annual cost savings of GBP400M

The Board has approved a new major restructuring programme, which is designed to significantly improve the competitiveness and efficiency of the Group's cost base with savings delivered primarily through supply chain optimisation and reductions in administrative costs. The new programme is expected to cost GBP 1.7 billion over the period to 2021, comprising cash costs of GBP 0.8 billion and non-cash costs of GBP 0.9 billion, and is expected to deliver annual savings of around GBP 400 million by 2021. These savings will be fully re-invested in the Group to help fund targeted increases in R&D and commercial support of new products. GSK said its new major restructuring programme expected to deliver annual cost savings of GBP 400 million by 2021. Charges expected to be GBP 0.8 billion cash and GBP 0.9 billion non-cash over next 3 years. CEO Emma Walmsley said: "With the recent new product launches, development of the new R&D approach and the successful buyout of the Consumer business, we have evaluated the Group's cost base and what is required to deliver competitive long-term growth and performance in each of the Group's three businesses. As a result, we are today announcing a new major restructuring programme, which aims to significantly improve the competitiveness and efficiency of the Group's cost base with savings delivered primarily through supply chain optimisation and reductions in administrative costs." She added: "Under Hal Barron's leadership, we are reallocating resources to support this new R&D approach, and savings realised from the new major restructuring programme will be used to help fund targeted increases in R&D spending as well as support new products. We believe the R&D approach outlined today will deliver the value we see in our pipeline for the benefit of patients and shareholders."

  • 25

    Jul

  • 25

    Jul

GSK GlaxoSmithKline
$41.20

0.26 (0.64%)

05/16/18
SPHN
05/16/18
INITIATION
Target $16
SPHN
Overweight
Codexis initiated with an Overweight at Stephens
Stephens analyst Drew Jones started Codexis (CDXS) with an Overweight rating and $16 price target, stating that the company's CodeEvolver platform technology has been sought by pharma partners Merck (MRK), GlaxoSmithKline (GSK) and Nestle (NSRGY) and he expects continued deeper adoption from other major industry players.
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

ZBRA

Zebra Technologies

$180.92

-16.74 (-8.47%)

13:40
07/18/19
07/18
13:40
07/18/19
13:40
Options
Notable vol spike in Zebra Technologies as shares sell off »

Notable vol spike in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

TELL

Tellurian

$6.98

0.31 (4.65%)

13:40
07/18/19
07/18
13:40
07/18/19
13:40
Recommendations
Tellurian analyst commentary  »

Tellurian higher after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JLL

Jones Lang LaSalle

$140.05

0.585 (0.42%)

13:32
07/18/19
07/18
13:32
07/18/19
13:32
Conference/Events
Jones Lang LaSalle management to meet with Mizuho »

Meeting with EVP Monahan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 06

    Aug

  • 06

    Aug

GOSS

Gossamer Bio

$19.60

-0.48 (-2.39%)

13:30
07/18/19
07/18
13:30
07/18/19
13:30
Options
Gossamer Bio call volume spikes on November purchase wit shares at 52wk lows »

Gossamer Bio call volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
07/18/19
07/18
13:25
07/18/19
13:25
Conference/Events
Cowen healthcare/biotech analysts to hold an analyst/industry conference call »

Healthcare Technology…

PEP

PepsiCo

$132.17

-0.6 (-0.45%)

13:24
07/18/19
07/18
13:24
07/18/19
13:24
Periodicals
Breaking Periodicals news story on PepsiCo »

PepsiCo in talks to buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
07/18/19
07/18
13:20
07/18/19
13:20
General news
Treasury's $14 B 10-year TIPS sale was on the soft side »

Treasury's $14 B…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/18/19
07/18
13:17
07/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/18/19
07/18
13:16
07/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$8.55

-0.03 (-0.35%)

13:15
07/18/19
07/18
13:15
07/18/19
13:15
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

13:09
07/18/19
07/18
13:09
07/18/19
13:09
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

13:09
07/18/19
07/18
13:09
07/18/19
13:09
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

TELL

Tellurian

$6.99

0.32 (4.80%)

13:05
07/18/19
07/18
13:05
07/18/19
13:05
Options
Tellurian call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:57
07/18/19
07/18
12:57
07/18/19
12:57
Conference/Events
Stephens architecture analysts to hold analyst/industry conference call nosymbol »

Analysts hold an…

EMR

Emerson

$64.26

-0.4 (-0.62%)

12:55
07/18/19
07/18
12:55
07/18/19
12:55
Options
Emerson put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 06

    Aug

  • 22

    Aug

  • 06

    Sep

12:45
07/18/19
07/18
12:45
07/18/19
12:45
General news
Treasury $14 B 10-year TIPS preview: the auction outlook is mixed. »

Treasury $14 B 10-year…

FB

Facebook

$200.15

-1.82 (-0.90%)

12:43
07/18/19
07/18
12:43
07/18/19
12:43
Periodicals
Instagram hiding 'likes' in more countries to ease pressure, Gadgets says »

Facebook's Instagram…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

DHR

Danaher

$141.79

2.19 (1.57%)

12:40
07/18/19
07/18
12:40
07/18/19
12:40
Recommendations
Danaher analyst commentary at Piper Jaffray »

Danaher price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 07

    Nov

AXP

American Express

$128.02

0.975 (0.77%)

, V

Visa

$179.16

(0.00%)

12:39
07/18/19
07/18
12:39
07/18/19
12:39
Earnings
Fly Intel: What to watch in credit card space earnings reports »

American Express (AXP),…

AXP

American Express

$128.02

0.975 (0.77%)

V

Visa

$179.16

(0.00%)

MA

MasterCard

$275.83

0.49 (0.18%)

UBER

Uber

$43.74

0.12 (0.28%)

LYFT

Lyft

$65.51

0.35 (0.54%)

WU

Western Union

$20.42

0.02 (0.10%)

BBVA

Banco Bilbao

$5.42

-0.055 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 23

    Jul

  • 30

    Jul

  • 01

    Aug

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 27

    Oct

  • 13

    Nov

BUD

AB InBev

$88.73

0.31 (0.35%)

, KKR

KKR

$25.38

-0.08 (-0.31%)

12:36
07/18/19
07/18
12:36
07/18/19
12:36
Periodicals
AB InBev weighs asset sales after calling off Asian IPO, WSJ reports »

Anheuser-Busch InBev…

BUD

AB InBev

$88.73

0.31 (0.35%)

KKR

KKR

$25.38

-0.08 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 25

    Jul

ESV

Ensco Rowan

$7.74

-0.16 (-2.03%)

12:35
07/18/19
07/18
12:35
07/18/19
12:35
Options
Ensco put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 27

    Aug

CHS

Chico's

$3.29

-0.13 (-3.80%)

12:34
07/18/19
07/18
12:34
07/18/19
12:34
Hot Stocks
Chico's FAS initiates Fort Myers lockdown after call over active shooter threat »

Chico's FAS issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPE

Callon Petroleum

$4.87

-0.35 (-6.71%)

12:33
07/18/19
07/18
12:33
07/18/19
12:33
Conference/Events
Callon Petroleum management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 19

    Jul

  • 27

    Aug

BUD

AB InBev

$88.64

0.22 (0.25%)

12:29
07/18/19
07/18
12:29
07/18/19
12:29
Hot Stocks
Breaking Hot Stocks news story on AB InBev »

AB InBev up 1% to $89.30…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

BUD

AB InBev

$88.64

0.22 (0.25%)

12:29
07/18/19
07/18
12:29
07/18/19
12:29
Periodicals
Breaking Periodicals news story on AB InBev »

AB InBev exploring asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.